New primary monoclonal antibodies · 16. April 2025

SYnAbs unique R&D and therapeutic monoclonal antibodies to CCR10 (GPR-2), C-C chemokine Receptor 10 GPCR transmembrane protein

New primary monoclonal antibodies · 10. April 2025

Valproic acid (VPA) is a widely used drug with narrow therapeutic window, necessitating precise monitoring of blood levels to avoid toxicity or sub-therapeutic effects. Traditional methods of measuring VPA have limitations in terms of sensitivity, specificity, and accuracy. In this context, SYnAbs has developed the best monoclonal antibodies against VPA.

New primary monoclonal antibodies · 02. October 2024

SYnAbs develops monoclonals to complex cancer epitopes to be used in theranostic oncology radioimmunotherapy treatments

New primary monoclonal antibodies · 19. September 2023

SYnabs mouse monoclonal antibodies to metalloproteinases proMMP9 and activated MMP9 (Gelatinase B) as diagnostic and therapeutic tools for immune diseases, neurological diseases and strokes

New primary monoclonal antibodies · 24. April 2023

CRP is synthesized by the liver in response to several inflammatory cytokines and is a well-established biomarker of inflammation and infection. Elevated CRP levels are associated with several diseases, including inflammatory bowel disease, rheumatoid arthritis, cardiovascular disease, infection, and cancer. SYnAbs Monoclonal antibodies offer several advantages for CRP diagnosis in a precision medicine context.